Metzger Michael A — SEC Form 4 filings
SEC reporting owner CIK 1507220. 14 Form 4 filings on record with FilingPulse; latest filed 2026-07-09.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-02-09 to 2026-07-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 8 filings — 249,736 shares, $4,404,012 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 157,307 shares @ $16.41 ($2,582,021) in Syndax Pharmaceuticals Inc, filed 2025-09-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | Chief Executive Officer, Director | 11 | — | 8 legs · 249,736 sh · $4,404,012 | 17 |
| Pyxis Oncology, Inc. (PYXS) | Director | 3 | — | — | 3 |
Form 4 filings — Metzger Michael A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-09 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Option exercise (M): 32,375 @ $6.38 · Sale (S): 32,375 @ $24.24 · Option exercise (M): 32,375 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Sale (S): 6,847 @ $18.99 | EDGAR |
| 2026-03-25 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Sale (S): 17,159 @ $21.03 | EDGAR |
| 2026-02-06 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 73,000 @ $0 · Grant/award (A): 144,600 @ $0 · Sale (S): 7,412 @ $20.62 · Grant/award (A): 440,000 (derivative) @ $20.43 | EDGAR |
| 2025-09-08 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Option exercise (M): 157,307 @ $10.90 · Sale (S): 157,307 @ $16.41 · Option exercise (M): 157,307 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Sale (S): 7,534 @ $9.29 | EDGAR |
| 2025-04-02 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-03-17 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Option exercise (M): 6,074 @ $7.20 · Option exercise (M): 6,074 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Option exercise (M): 7,814 @ $7.20 · Sale (S): 7,814 @ $15.05 · Option exercise (M): 7,814 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Sale (S): 13,288 @ $15.50 | EDGAR |
| 2025-02-07 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 60,500 @ $0 · Grant/award (A): 89,000 @ $0 · Grant/award (A): 364,000 (derivative) @ $14.65 | EDGAR |
| 2024-06-10 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 70,683 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 107,250 @ $0 · Grant/award (A): 39,000 @ $0 · Grant/award (A): 214,500 (derivative) @ $22.28 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1507220 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →